Israeli Biotech Sector Maturing, Seeking U.S. Investors
By Vicki Brower
Friday, December 10, 2010
NEW YORK In spite of having the world's highest number of life science patents per capita, a highly developed academic research infrastructure, and entrepreneurial know-how, Israel still has trouble commercializing its discoveries due to a number of factors, mostly financing. But the Israeli biotech industry is finally coming of age, according to 14 company presentations at this week's Tel Aviv Stock Exchange (TASE)-NASDAQ Biomed Conference held at NASDAQ's New York headquarters.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.